Thursday 16 October, 2025
Objectives: Darunavir (DRV) is a widely used protease inhibitor in de novo or pretreated HIV patients, combined with a background…
Read morePoster: Drug/Disease Modelling - Infection
Model-informed evaluation of prolonged versus short infusion regimens of meropenem based on two strategies of preclinical-clinical translation
Thursday 16 October, 2025
Objectives: Pharmacokinetic-pharmacodynamic (PKPD) models based on in vitro time-kill studies of antibiotics have emerged as indispensable tools to identify efficacious…
Read moreAn Immune quantitative network aimed for viral hepatitis B
Thursday 16 October, 2025
Background: The liver is a well-known immunotolerogenic environment characterized by absence of exacerbated immune responses, thus providing the adequate setting…
Read moreMechanism-Based Modeling In Chronic Heptatis B
Thursday 16 October, 2025
Objectives: Chronic hepatitis B virus (HBV) infection contributes to a severe disease burden all around the world. In order to gain…
Read moreAssessment of translation of PKPD relationship from animal to human for malaria compounds
Thursday 16 October, 2025
Introduction: Activity of antimalarial candidate compounds is first tested in severe combined immunodeficient (SCID) mice engrafted with human erythrocytes and…
Read moreEstablishing correlates of protection for herpes zoster infection via MBMA analysis
Thursday 16 October, 2025
Introduction: Shingles, also known as herpes zoster (HZ), is a painful illness resulting from varicella-zoster virus (VZV) reactivation. It is…
Read morePopulation pharmacokinetics of LXE408 in healthy volunteers and dose predictions for adults and pediatric patients with visceral leishmaniasis
Thursday 16 October, 2025
Objectives: To describe the population pharmacokinetics of LXE408, a novel kinetoplastid proteasome inhibitor, after oral administration in healthy volunteers in…
Read moreLinking rifampicin exposure to treatment response over 6 months in patients with pulmonary tuberculosis
Thursday 16 October, 2025
Objectives: Rifampicin (RIF) is the most important component of first-line anti-tuberculosis (TB) therapy, but the optimal dosing of this pivotal drug…
Read moreMeta-analysis of rifampicin exposure and mortality in three randomized controlled phase II tuberculosis meningitis trials
Thursday 16 October, 2025
Objectives: Tuberculosis meningitis (TBM) is the most severe form of tuberculosis, with up to 50% mortality mostly within the first 2…
Read moreDeveloping SARS-CoV-2 viral dynamic model in patients with COVID-19 based on amount of viral RNA and viral titer
Thursday 16 October, 2025
Introduction: Target cell-limited models involve the process from viral infection to viral clearance in humans, and they are often used…
Read more